Navigation Links
Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
Date:11/5/2013

ientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; our lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an "emerging growth company," as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends.  These and other important factors discussed under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, eve
'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
7. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
11. Fate Therapeutics Strengthens Its iPSC Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The global market for molecular diagnostics is ... to a new study by Grand View Research, Inc. ... subsequent introduction of advanced cancer diagnostic technologies are expected ... next six years. Moreover, the growing global base of ... with disease triggering lifestyle habits such as smoking and ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2014 on Wednesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2014 ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... to IT Nirvana, and I like it. , ,OK, maybe thats ... the VP of IT at Rayovac , it sounds like ... fighting for respect. They get invited to the table when its ... They arent nearly deaf from the constant ringing of alarm bells. ...
... Rayovac signs $1.2 billion deal for United Industries , ... Rayovac Corp. has negotiated a contract to purchase St. ... and common stock, with the deal expected to close in ... the lawn and garden product market, obtaining United brands such ...
... of digital convergence on Thursday at the Consumer Electronics Show ... service. , ,Designed as part of the companys plan ... digital video recording and Internet service in a set-top box. ... connection. , ,In his keynote address, SBC chairman Edward Whitacre ...
Cached Biology Technology:Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT 2Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT 3Is Rayovac IT Nirvana? An exclusive interview with Rick Dempsey, VP of IT 4Tech Digest: Rayovac, Inacom, TomoTherapy, Regal-Beloit, Modine 2SBC blends TV, video, music and the Internet in a new media box 2
(Date:7/31/2014)... German . ... to a sponge that soaks up liquids. Hence, these ... greenhouse gases. However, loading of many MOFs is inhibited ... now report in Nature Communications that the ... This can be prevented by water-free synthesis and storing ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
(Date:7/31/2014)... A Florida State University researcher found that bacteria in ... components of the oil released during the Deepwater Horizon ... the most toxic contaminants. , In two new studies ... Mason found a species of bacteria called Colwellia ... ethylbenzene and xylene compounds that were released as part ...
Breaking Biology News(10 mins):Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... class of drugs used by millions worldwide to effectively ... impact in Multiple Sclerosis (MS) patients treated with high ... the Montreal Neurological Institute (MNI), McGill University, demonstrates that ... in the central nervous system. The findings, published in ...
... a young person who dies suddenly should always be ... identify if they too are at risk of sudden ... European Society of Human Genetics today (Tuesday 26 May). ... fellow at the Department of Cardiogenetics, Academic Medical Centre, ...
... have been able to identify genetic factors that influence the ... Ms Lisette Stolk, a researcher from Erasmus MC, Rotterdam, ... of Human Genetics today ( Monday 25 May) that a ... eventually help to improve the clinical treatment of infertile women. ...
Cached Biology News:One size does not fit all 2Comprehensive cardiogenetic testing for families of sudden unexplained death victims can save lives 2Identification of genetic variants affecting age at menopause could help improve fertility treatment 2
... Osmometer for both 0.2 and 2.0 mL samples for freezing point determinations. ... Bar code reading capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: